AMBITION 1NCT07931495
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in glycated haemoglobin (HbA1c)
Timeframe: From baseline (week 0) to week 44
Secondary (7)
Relative change in body weight
Change in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Change in triglycerides
Change in non-high-density lipoprotein (non-HDL) cholesterol
Change in high sensitivity C-reactive protein (hsCRP)
Show 2 moreShow less
Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals)
Change in systolic blood pressure
Arms and interventions
ZenagamtideExperimental
Participants will receive zenagamtide subcutaneously.
PlaceboPlacebo comparator
Participants will receive placebo matched to zenagamtide subcutaneously.
Drugs: Zenagamtide, Placebo
Sites
48 sites in 8 countries
United States 12, Poland 7, Romania 6, Slovakia 6, Turkey (Türkiye) 6, China 5, Japan 5, Puerto Rico 1